Cumulative evidence from pivotal randomized trials demonstrates that DAT with a NOAC plus a P2Y12 inhibitor provides a safer and equally effective alternative to conventional triple therapy in patients with AF undergoing PCI. This evidence concerns the gene P2RY12 and atrial fibrillation.